Extract from "Clinical Evidence": Obesity

British Medical Journal

Volumn 322, Issue 7299, 2001, Pages 1406-1409

  Arterburn, D ^a   Noel P H ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; DEXFENFLURAMINE; FENFLURAMINE; FLUOXETINE; MAZINDOL; PHENTERMINE; PHENYLPROPANOLAMINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; ANOREXIGENIC AGENT; ORAL CONTRACEPTIVE AGENT;

AMNESIA; ANOREXIA; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; HEADACHE; HUMAN; META ANALYSIS; OBESITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; TREATMENT OUTCOME; WEIGHT REDUCTION; ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; HYPERTENSION; INTESTINE ABSORPTION; MALE; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK; VALVULAR HEART DISEASE;

ADULT; AGED; APPETITE DEPRESSANTS; CEREBROVASCULAR ACCIDENT; CONTRACEPTIVES, ORAL; CORONARY DISEASE; FEMALE; HEART VALVE DISEASES; HUMANS; HYPERTENSION; HYPERTENSION, PULMONARY; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; OBESITY; RANDOMIZED CONTROLLED TRIALS; RISK;

EID: 0035832437     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. The spread of the obesity epidemic in the United States 1991-1998
2. Obesity: Etiology
3. Obesity: Overview of therapy for obesity
4. Annual deaths attributable to obesity in the United States
5. Sibutramine: A serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity
6. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: A 1-year, double-blind, placebo-controlled multicenter trial
7. Sibutramine produces dose-related weight loss
8. Efficacy and tolerability of sibutramine in obese patients: A dose-ranging study
9. Sibutramine in weight control: A dose-ranging, efficacy study
10. Long-term maintenance of weight loss after a very-low calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine
11. Long-term weight loss with sibutramine
12. Comparison of continuous and intermittent anorectic therapy in obesity
13. Controlled comparative investigation of mazindol, D-amphetamine, and placebo
14. Long-term use of diethlyproprion in obesity
15. The long-term management of obesity in general practice
16. Periodic health examination, 1999 update: 1. Detection, prevention and treatment of obesity. Canadian Task Force on Preventive Health Care
17. Long-term pharmacotherapy in the management of obesity
18. Fluoxetine: A randomized clinical trial in the treatment of obesity
19. Fluoxetine in the treatment of obese type II diabetic patients
20. Behavioral and pharmacological treatments for obesity: An experimental comparison
21. Controlled trial of behaviour therapy, pharmacotherapy, and their combination in the treatment of obesity
22. Long term weight control study: The National Heart, Lung, and Blood Institute funded multimodal intervention study
23. Clinical studies with phenylpropanolamine: A metaanalysis
24. Valvular heart disease induced by anorectic drugs
25. Delayed onset of pulmonary hypertension associated with an appetite suppressant, mazindol: A case report
26. Appetite suppressants and primary pulmonary hypertension in the United Kingdom
27. Psychosis following readministration of diethylproprion: A possible role for kindling?
28. Treatment of depression - Newer pharmacotherapies
29. Scientific and legal issues in fenfluramine/dexfenfluramine litigation
30. Valvular heart disease associated with fenfluramine-phentermine
31. Pharmacological treatment of obesity: Present status
32. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine and phentermine/fenfluramine
33. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo
34. Appetite-suppressant drugs and the risk of primary pulmonary hypertension
35. Use of prescription weight loss pills among U.S. adults in 1996-1998
36. Orlistat: No hurry
37. Orlistat in the long-term treatment of obesity in primary care settings
38. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity
39. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study
40. Role of orlistat in the treatment of obese patients with type 2 diabetes: A 1-year randomized double-blind study
41. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
42. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial
43. One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor
44. Caution when using oral contraceptive pills with Orlistat